Eribulin + Adriamycin + Cyclophosphamide
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammatory Breast Cancer
Conditions
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Trial Timeline
Feb 26, 2016 → Dec 1, 2026
NCT ID
NCT02623972About Eribulin + Adriamycin + Cyclophosphamide
Eribulin + Adriamycin + Cyclophosphamide is a phase 2 stage product being developed by Eisai for Inflammatory Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02623972. Target conditions include Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast.
What happened to similar drugs?
10 of 20 similar drugs in Inflammatory Breast Cancer were approved
Approved (10) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02623972 | Phase 2 | Active |
Competing Products
20 competing products in Inflammatory Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 50 |
| CT-P13 | Celltrion | Phase 3 | 36 |
| Subcutaneous infliximab CT-P13 Remsima®SC | Celltrion | Pre-clinical | 22 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 47 |
| fidaxomicin | Astellas Pharma | Approved | 43 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 29 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 42 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 35 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 29 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 39 |
| MORF-057 | Eli Lilly | Phase 2 | 35 |
| LY3009104 | Eli Lilly | Phase 1 | 29 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| Risankizumab | AbbVie | Approved | 43 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 36 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 29 |
| Human Papillomavirus Vaccine | Merck | Approved | 43 |
| Pembrolizumab | Merck | Phase 2 | 31 |
| Gardasil vaccine | Merck | Pre-clinical | 26 |
| Bezlotoxumab | Merck | Approved | 35 |